Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

UNBELIEVABLE: This strong buy stock has more than tripled today should you buy it here - The Untold Story

Praxis Precision Medicines (PRAX) shares nearly tripled on Thursday after the biotechnology firm reported promising late-stage results for its experimental drug ulixacaltamide. 

According to the company’s press release, ulixacaltamide significantly improved daily functioning in patients with essential tremor across two Phase 3 trials. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.